30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Seikagaku's 3QFY16 Revenue -

Seikagaku posted 3QFY16 revenue of ¥7.0BB (~US $40.1MM), -35.2% vs. the prior year. (Period ended 12/31/16)

The reporting period concludes Seikagaku’s 9-month sales for its calendar year. Within that period, revenue fell by -5.6% vs. the prior year, impacted by yen appreciation and government price reductions in Japan, despite higher sales volumes of Gel-One in the U.S.

Domestically, ARTZ deliveries increased slightly following an introduction of new syringes, while China sales declined due to government price pressure and factors such as yen appreciation.

U.S. Gel-One sales held steady reflecting focus of marketing partner (Zimmer Biomet), while U.S. SUPARTZ FX sales fell slightly against continued competition for multi-injection products.

Within the past quarter, the company entered into an exclusive agreement with Zimmer Biomet for U.S. distribution of VISCO-3, a 3-injection hyaluronic acid-based viscosupplement for the treatment of knee osteoarthritis pain.

Sources: Seikagaku Corporation; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.